02. Natera, Inc. (NASDAQ:NTRA)
Upside Potential: 20%
On January 29, The Goldman Sachs Group reiterated its bullish stance on Natera, Inc. (NASDAQ:NTRA), a prominent player in the genetic testing industry, maintaining a “BUY” rating on the stock. Additionally, Goldman Sachs increased the price target for Natera, Inc. (NASDAQ:NTRA) from $64.00 to $80.00, indicating a substantial upside potential of 20% relative to the closing market price on January 29. This reaffirmation of confidence by Goldman Sachs underscores the firm’s positive outlook on Natera’s position and growth prospects within the genetic testing sector. By maintaining a “BUY” rating, Goldman Sachs signals its belief that Natera represents an attractive investment opportunity with favorable prospects for long-term growth and value appreciation. The raised price target of $80.00 reflects Goldman Sachs’ optimistic view on Natera, Inc. (NASDAQ:NTRA) future performance and earnings potential. This adjustment signifies Goldman Sachs’ belief that Natera’s stock is currently undervalued relative to its expected earnings trajectory and growth opportunities. Goldman Sachs’ analysis and price target revision for Natera are likely to have an impact on investor perceptions and contribute to ongoing discussions about Natera, Inc. (NASDAQ:NTRA) competitive positioning and growth trajectory within the genetic testing industry. As a leading provider of genetic testing services, Natera, Inc. (NASDAQ:NTRA) continues to attract attention from analysts and investors, with Goldman Sachs expressing confidence in its ability to deliver strong returns for shareholders.
Alger Spectra Fund made the following comment about Natera, Inc. (NASDAQ:NTRA) in its Q2 2023 investor letter:
“Natera, Inc. (NASDAQ:NTRA) is a specialty lab providing genetic testing services in the reproductive health, oncology and transplant markets. Reproductive health tests are run to screen for common genetic disorders such as trisomy 13, 18, and 21 in pregnant women – these tests are also known as non-invasive prenatal testing (NIPT). The company’s oncology franchise is led by Signatera, a test used to detect minimal residual disease (MRD) – the applications of this test are primarily to monitor therapy response and detect cancer recurrence. Lastly, Natera’s transplant franchise is led by Prospera, a test used to monitor transplant organ rejection. Natera’s tests are all based on the company’s proprietary liquid biopsy platform to detect cell-free DNA. Shares detracted from performance this quarter after the company reported lower than expected fiscal first quarter gross margins. Moreover, we believe investors sold shares this quarter following a strong first quarter rally after the Centers for Medicare & Medicaid Services (CMS) announced they would cover Natera’s Signatera Breast tests. Despite this quarter’s decline in share price, the company reported solid quarterly revenues that beat analyst estimates, driven by strong volumes in women’s health and management raised its fiscal 2023 revenue guidance above consensus.”
